New options for metastatic breast cancer

Clinical Journal of Oncology Nursing

Volumn 13, Issue SUPPL. 1, 2009, Pages 11-18

  Frye, Debra K ^a   Mahon, Suzanne M ^b   Palmieri, Frances M ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67349255906     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/09.CJON.S1.11-18     Document Type: Article

References (22)

1. Abraham, J. (2007). Ixabepilone in metastatic breast cancer: Firstin-class antineoplastic agent offers a new chemotherapy option where other drugs have failed. Community Oncology, 4(11), 660-664.
2. Bristol-Myers Squibb Company. (2007). Highlights of prescribing information: Ixempra™ kit (ixabepilone). Retrieved August 27, 2008, from http://packageinserts.bms.com/pi/pi_ixempra.pdf
3. Bristol-Myers Squibb Company. (2008). Patient information: Ixempra ™ kit (ixabepilone). Retrieved August 27, 2008, from http://ixempra.com/pdf/Patientinfo.pdf
4. Denduluri, N., Low, J.A., Lee, J.J., Berman, A.W., Walshe, J.M., Vatas, U., et al. (2007). Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. Journal of Clinical Oncology, 25(23), 3421-3427.
5. Dvorak, H.F. (2002). Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of Clinical Oncology, 20(21), 4368-4380.
6. ® (bevacizumab) [Package insert]. Retrieved August 27, 2008, from http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf
7. Goodin, S., Kane, M.P., & Rubin, E.H. (2004). Epothilones: Mechanism of action and biologic activity. Journal of Clinical Oncology, 22(10), 2015-2025.
8. Heer, K., Kumar, H., Read, J.R., Fox, J.N., Monson, J.R., & Kerin, M.J. (2001). Serum vascular endothelial growth factor in breast cancer: Its relation with cancer type and estrogen receptor status. Clinical Cancer Research, 7(11), 3491-3494.
9. Lee, F., Camuso, A., Castenada, S., Flefleh, C., Ingio, I., Kan, D., et al. (2006). Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenographs [Abstract 12017]. Journal of Clinical Oncology, 24(Suppl. 18), 59s.
10. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., et al. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine, 357(26), 2666-2676.
11. Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh, M.A., Marcom, P.K., Fehrenbacher, L., et al. (2005). Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology, 23(4), 792-799.
12. National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Retrieved August 27, 2008 from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
13. National Comprehensive Cancer Network. (2008). NCCN Clinical Practice Guidelines in OncologyTM: Cancer-related fatigue [v.1.2008]. Retrieved August 22, 2008, from http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf
14. National Heart, Lung, and Blood Institute. (2003). JNC 7 Express. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [NIH Publication No. 03-5233]. Washington, DC: U.S. Department of Health and Human Services.
15. Oncologic Drugs Advisory Committee. (2007). Summary minutes of the December 5, 2007, meeting. Washington, DC. Oncology Nursing Society. (n.d.a). ONS Putting Evidence Into Practice ®: Fatigue detailed PEP card. Retrieved January 20, 2009, from http://ons.org/outcomes/volume1/fatigue/pdf/FATIGUE-DetailedPEPCard4-28-06.pdf
16. ®: Peripheral neuropathy detailed PEP card. Retrieved January 20, 2009, from http://www.ons.org/outcomes/volume2/peripheral/pdf/PEPCardDet_peripheral.pdf
17. Perez, E.A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L., et al. (2007). Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 25(23), 3407-3414.
18. Reidy, D.L., Chung, K.Y., Timoney, J.P., Park, V.J., Hollywood, E., Sklarin, N.T., et al. (2007). Bevacizumab 5 mg/kg can be infused safely over 10 minutes. Journal of Clinical Oncology, 25(19), 2691-2695.
19. Roche, H., Yelle, L., Cognetti, F., Mauriac, L., Bunnell, C., Sparano, J., et al. (2007). Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. Journal of Clinical Oncology, 25(23), 3415-3420.
20. Seidman, A.D. (2006). Systemic treatment of breast cancer. Two decades of progress. Oncology, 20(9), 983-990.
21. Thomas, E., Tabernero, J., Fornier, M., Conte, P., Fumoleau, P., Lluch, A., et al. (2007). Phase II clinical trial of ixabepilone, an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. Journal of Clinical Oncology, 25(23), 3399-3406.
22. Thomas, E.S., Gomez, H.L., Li, R.K., Chung, H.C., Fein, L.E., Chan, V.F., et al. (2007). Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 25(33), 5210-5217.